Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Age accumulates mitochondrial DNA mutations and reduces oxidative phosphorylation efficiency
Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects
Per-batch reported on 10mL Sterile Glass Research Vial Aluminum Crimp Seal Handle per institutional protocol Available upon request Discrete packaging, domestic priority Every Aurevra Bio compound is documented with a per-batch COA identifying compound, CAS number, lot, manufacture date, purity, and HPLC methodology
Read mapping of RNA-seq data was done by the STAR aligner (v.2.5.4b) [73] using the genome of strain MBM as a reference
US$ 27.69
US$ 21.10
US$ 25.95
US$ 29.27
US$ 28.76
